<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04524676</url>
  </required_header>
  <id_info>
    <org_study_id>PLAEGV</org_study_id>
    <nct_id>NCT04524676</nct_id>
  </id_info>
  <brief_title>Oxaliplatin-induced Portal Hypertension</brief_title>
  <official_title>Construction and Evaluation of the Early Identification and Individualized Treatment for Oxaliplatin-induced Portal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal&#xD;
      cancer and it has significantly improved the outcomes in patients with colorectal cancer.&#xD;
      However, hepatotoxicity is the potentially problematic adverse effect of oxaliplatin. The&#xD;
      pathological evaluation of non-tumoral liver from patients with advanced colorectal cancer&#xD;
      undergoing neoadjuvant oxaliplatin-based treatment has provided histological evidence of&#xD;
      hepatic sinusoidal injury. Oxaliplatin-induced sinusoidal injury can persist for more than 1&#xD;
      year after the completion of chemotherapy, and the increase in splenic volume may be a&#xD;
      predictor of irreversible sinusoidal damage. In this current study, we aim to evaluate the&#xD;
      efficacy of individualized treatment in patients with oxaliplatin-induced gastroesophageal&#xD;
      varices after colorectal cancer surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 31, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year rebleeding rate</measure>
    <time_frame>1 year</time_frame>
    <description>1-year rebleeding rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year death rate</measure>
    <time_frame>1 year</time_frame>
    <description>1-year death rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of portal hypertension</measure>
    <time_frame>1 year</time_frame>
    <description>The occurrence of complications of portal hypertension including ascites, liver failure, et al.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Gastroesophageal Varices Hemorrhage</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Received Oxaliplatin-based Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Individualized Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Individualized Treatment</intervention_name>
    <description>Patients under evaluation including hepatic venous pressure gradient (HVPG) and contrast-enhanced computed tomography of portal venous. For those patients with a HVPG ≥12mmHg or with extraluminal para-gastric vein will under transjugular intrahepatic portosystemic shunt and others receive endoscopic treatment.</description>
    <arm_group_label>Individualized Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sign written informed consent&#xD;
&#xD;
          -  Male or female patients aged 18-75&#xD;
&#xD;
          -  diagnosed as portal hypertension by contrast-enhanced computed tomography&#xD;
&#xD;
          -  and confirmed gastroesophageal varices by upper digestive endoscopy;&#xD;
&#xD;
          -  had a history of oxaliplatin-based chemotherapy after colorectal cancer surgery;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  combined known etiologies of chronic liver disease, including hepatitis, primary&#xD;
             biliary cirrhosis, schistosomiasis, and non-alcoholic fatty liver disease.&#xD;
&#xD;
          -  with colorectal cancer required further anti-tumor treatment&#xD;
&#xD;
          -  Other factors judged by the investigator that may affect the safety of the subject or&#xD;
             the compliance of the trial. Such as serious illnesses (including mental illness) that&#xD;
             require combined treatment, serious laboratory abnormalities, or other family or&#xD;
             social factors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Gastroenterology and Hepatology</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaoquan HUANG</last_name>
      <phone>008618801733835</phone>
      <email>huang.xiaoquan@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Shiyao CHEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Huang X, Li F, Wang L, Xiao M, Ni L, Jiang S, Ji Y, Zhang C, Zhang W, Wang J, Chen S. Endoscopic treatment of gastroesophageal variceal bleeding after oxaliplatin-based chemotherapy in patients with colorectal cancer. Endoscopy. 2020 Sep;52(9):727-735. doi: 10.1055/a-1157-8611. Epub 2020 May 7.</citation>
    <PMID>32380558</PMID>
  </results_reference>
  <results_reference>
    <citation>Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S, Azoulay D, Bismuth H, Castaing D, Adam R. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006 Nov 1;24(31):4983-90.</citation>
    <PMID>17075116</PMID>
  </results_reference>
  <results_reference>
    <citation>Iwai T, Yamada T, Koizumi M, Shinji S, Yokoyama Y, Takahashi G, Takeda K, Hara K, Ohta K, Uchida E. Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX. J Surg Oncol. 2017 Dec;116(7):947-953. doi: 10.1002/jso.24756. Epub 2017 Sep 6.</citation>
    <PMID>28876454</PMID>
  </results_reference>
  <results_reference>
    <citation>Ward J, Guthrie JA, Sheridan MB, Boyes S, Smith JT, Wilson D, Wyatt JI, Treanor D, Robinson PJ. Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. J Clin Oncol. 2008 Sep 10;26(26):4304-10. doi: 10.1200/JCO.2008.16.1893.</citation>
    <PMID>18779617</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Shiyao Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>portal hypertension</keyword>
  <keyword>gastroesophageal variceal bleeding</keyword>
  <keyword>colorectal carcinoma</keyword>
  <keyword>splenomegaly</keyword>
  <keyword>oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

